Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. - sprookjes - yvandenbroek - TriplyDB

Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.

Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.

http://www.wikidata.org/entity/Q33937093

about

Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy Menopausal status and hepatic steatosis in a general female population Overweight, physical activity, tobacco and alcohol consumption in a cross-sectional random sample of German adults.Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy.Development of an image analysis screen for estrogen receptor alpha (ERα) ligands through measurement of nuclear translocation dynamics A maternal "junk food" diet in pregnancy and lactation promotes nonalcoholic Fatty liver disease in rat offspring Uridine prevents tamoxifen-induced liver lipid droplet accumulation.NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?Identification of compounds by high-content screening that induce cytoplasmic to nuclear localization of a fluorescent estrogen receptor α chimera and exhibit agonist or antagonist activity in vitro.The influence of metabolic factors for nonalcoholic Fatty liver disease in women.A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.Secondary causes of nonalcoholic fatty liver disease.Histological assessment of non-alcoholic fatty liver disease.Non-alcoholic fatty liver disease: further expression of the metabolic syndrome.Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer.Liver injury induced by anticancer chemotherapy and radiation therapy.Grand challenges in cancer endocrinology: endocrine related cancers, an expanding concept.Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro.Case definition and phenotype standardization in drug-induced liver injury.ASH and NASH.Central role of mitochondria in drug-induced liver injury.Defining a reference set to support methodological research in drug safety.SEURAT-1 liver gold reference compounds: a mechanism-based review.Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD).Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model.Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies.Drug-induced hepatotoxicity in cancer patients - implication for treatment.The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights.Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study - sample of São José do Rio Preto.Using controlled clinical trials to learn more about acute drug-induced liver injury.Invasive and non-invasive investigations for non-alcoholic steatohepatitis (NASH): the need for biochemical markers.Need for weight management among postmenopausal early breast cancer patients receiving adjuvant endocrine therapy.

P2860

Q26798157-5BCD425B-4B1F-4C5A-B0DD-D96847EFDD40 Q28079826-389934FB-F001-4777-96E2-20D2A88B8830 Q28300092-02606809-B494-4665-A42D-5140DAB355D1 Q28762848-AA8E7D36-F679-44EB-AFD9-F0A8888B46DF Q30823603-BDEDB210-0678-46A2-944E-81E4DEB47B34 Q33649441-311B0F06-206D-450C-ACED-ACE4A36E300A Q33684356-CB81AAD1-0E7B-4C79-BDA2-8A95B2035F77 Q33772350-90E71261-D3D1-4E15-A96B-6FCAA8723760 Q33781931-B2087EEA-21E4-4AE6-87CF-8D5281D99DE5 Q33844463-373DB0E5-5817-41CD-B2AC-5E74571414CE Q34593200-4E1BF334-A0DC-43D6-9ABA-A1377A5C01F7 Q34992508-4E62EB7D-EABC-4E6E-969D-6A01C2CFAB6B Q35564120-3E2F8A93-A578-49B4-9C24-4F2A5266C624 Q35713616-14EBE64B-4D59-47FA-8CFE-1370C939416D Q35929072-3FFB1472-D6B6-44DB-853F-F3F98CA6A913 Q36634377-4C740E8A-5CE6-4BC0-A618-21864129048F Q36734086-1D37E2E2-C23E-4FD6-B678-1CA3412C6249 Q37008398-65EDE5CE-686F-4AF9-9764-F5336F072BAF Q37067634-B9151EF4-8B1E-4D11-882A-EDFA778A4522 Q37219802-1C3CB009-AFB6-4CC7-92A8-C444A07BE7FD Q37665974-900A3E8F-B946-4F7D-AF64-4CC98A8C93AB Q37684018-391F6AFF-7654-4353-B3DB-D73273BDD51D Q37872195-D8CFF63D-FBA4-46E6-BE06-801C5CE24A89 Q37898415-ADAB9562-2358-4C3B-8FDB-16DBD5C611C8 Q37926590-756BBB12-6264-4AE0-9848-9042A32B6810 Q38156066-2F488FEC-7B20-454C-9655-88627499D38C Q38268013-588C11F7-19D8-4522-A8D2-F0104EC54D41 Q38552380-5C13830D-750D-4FCB-A7B4-88DE706A79E2 Q38642356-3326BD03-7FF1-42FF-AF21-B118927EB4E8 Q38687132-36F9D7E7-5AB8-4ED1-95E9-D1E40A5CB632 Q38791485-75FE072A-9DB0-4F8E-B1A3-5D8DA75A81CE Q38845891-CDE3852E-60F1-4D33-BE54-334FFCFB49EB Q39129668-3710A741-BE95-499E-B557-15359B51065F Q39678446-AA16774C-F738-48BA-B9B3-0919EF78BDC6 Q45833400-274E6302-576A-45BE-A72E-A3B4E2BA4D28 Q46960316-8704B020-5F28-4C85-8068-340ABD4A202A Q47370570-E50634A8-FDD2-4676-BA11-D705C7289779

P2860

Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.

http://www.wikidata.org/entity/Q33937093

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Incidence and risk factors for ...... moxifen chemoprevention trial.

@ast

Incidence and risk factors for ...... moxifen chemoprevention trial.

@en

type

label

Incidence and risk factors for ...... moxifen chemoprevention trial.

@ast

Incidence and risk factors for ...... moxifen chemoprevention trial.

@en

prefLabel

Incidence and risk factors for ...... moxifen chemoprevention trial.

@ast

Incidence and risk factors for ...... moxifen chemoprevention trial.

@en

P1433

Q33937093-FC66A254-A5F3-4C5B-98B0-165B6ECD0BE7

P1476

Q33937093-6188B314-D173-48B5-927C-2128AA6EA572

P2093

Q33937093-03276846-1F5D-43C5-8ED1-7535AFEDFFEA

Q33937093-122FE0C6-6934-4003-8F3C-C9A2D3670044

Q33937093-1C799E0C-6A88-4A64-A4AE-D028B1C360E4

Q33937093-39106BEE-EA74-41F5-B17E-9E234508C34D

Q33937093-3E7BA42D-FF9D-4D3E-94C0-81E9F6A75701

Q33937093-44A9D9D3-EAD2-4998-A021-86BBC287D13E

Q33937093-7205B382-7C9A-4E68-8D88-E3C4A8B3D256

Q33937093-D0847CCD-6177-4ED3-B80C-49B085D17CE9

Q33937093-D3758C98-E939-4322-A0DB-2EEFDC40D978

Q33937093-EF462481-414D-4EF7-9E54-21E2B3F1F1F7

P2860

Q33937093-0278D38C-81B7-40BB-B30B-7754B1F68C8A

Q33937093-1288A90F-E39D-4B1A-89AF-0A578C7792AD

Q33937093-13EE773B-2C84-4759-B5AF-E9F8C08D3EDB

Q33937093-28FBBFCF-9BF2-4244-A261-5085A782AC37

Q33937093-2F84A7EF-758A-40DE-A310-277C3B414EF8

Q33937093-3783BDC8-23D2-4B34-B4B6-7128B90FFE3D

Q33937093-3920B85F-2595-48D0-BB49-10721C3ADC7D

Q33937093-3CF6AA57-55A6-4073-BFAF-2F8364461025

Q33937093-4ED8DA62-1147-4C9B-A076-89A039258267

Q33937093-552024C3-351A-4CAD-A179-070AA66EF7AE

P304

Q33937093-99863711-4C4E-40B6-BB8A-DC40A9C70093

P31

Q33937093-A35D75E6-75D1-427D-AA00-E35557B933EE

P356

Q33937093-60866372-5F14-4DAD-86C7-B8F7E7E5B3B7

P407

Q33937093-0E8FB3F3-8387-4B27-897A-59DAA35D53CF

P433

Q33937093-054CF2B6-140E-4473-A88B-596AD189B756

P478

Q33937093-E1D8DC03-EAB3-4005-AB83-ED1FB8103E14

P50

Q33937093-66F31D4A-5594-4602-9760-236C25FBF3FE

Q33937093-A77541F1-7D1C-43E5-B40E-540C33830FDF

Q33937093-C5126BE5-74E8-4B76-B8C7-9E9FBE7830FC

Q33937093-CA123F68-7A8F-4C34-92AC-4F70B79DA959

P577

Q33937093-6A8C6263-9861-44A2-9B01-279BFA28D2FD

P698

Q33937093-FDD38210-06E8-4BD2-8572-DA138D6C8A70

P921

Q33937093-6F2013BD-1F7D-4784-8936-E5438709B7CD

P932

Q33937093-043E0369-3A32-49DC-93B4-52BBA1510831

P356

BMJ.38391.663287.E0

P1433

P1476

Incidence and risk factors for ...... moxifen chemoprevention trial.

@en

P2093

Alberto Colombo

http://www.w3.org/2001/XMLSchema#string

Andrea Decensi

http://www.w3.org/2001/XMLSchema#string

Donata Casadei-Giunchi

http://www.w3.org/2001/XMLSchema#string

Franco Desiderio

http://www.w3.org/2001/XMLSchema#string

Franco Monasterolo

http://www.w3.org/2001/XMLSchema#string

Marco Maggioni

http://www.w3.org/2001/XMLSchema#string

Nicole Rotmensz

http://www.w3.org/2001/XMLSchema#string

Paola Castellana

http://www.w3.org/2001/XMLSchema#string

Sonia Rossi

http://www.w3.org/2001/XMLSchema#string

Umberto Veronesi

http://www.w3.org/2001/XMLSchema#string

P2860

Liver fibrosis in overweight patients

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Cirrhosis with steatohepatitis after adjuvant tamoxifen

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Test validity of periodic liver function tests in a population of Japanese male bank employees.

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?

Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.

P304

932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.38391.663287.E0

http://www.w3.org/2001/XMLSchema#string

P407

P433

7497

http://www.w3.org/2001/XMLSchema#string

P478

330

http://www.w3.org/2001/XMLSchema#string

P50

Patrick Maisonneuve

Marcello Persico

Tommaso Stroffolini

P577

2005-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15746106

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

P932

556336

http://www.w3.org/2001/XMLSchema#string